Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zerbaxa vs Meropenem in cIAI
NCT01445678Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of ceftolozane + tazobactam in Intra-abdominal infection (IAI), sponsored by Merck & Co.. Started Dec 2011; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT01445678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01445678.